article 3 months old

Don’t Sell Progen Just Yet, Intersuisse Says

Australia | May 17 2006

By Chris Shaw (Tokyo)

Having previously identified Progen (PGL) as a Speculative Buy, Intersuisse has had its view reinforced by news the US Food & Drug Administration (FDA) has asked the company for details regarding a proposed Phase III trial of one of its treatments.

The treatment is for liver cancer and involves the company’s PI-88 compound, for which it is currently conducting Phase II trials. As the broker notes, the FDA move should help speed up the development process, as Phase III trials are now likely to begin in the middle of next year.

It should also lower the development cost for the company, as the broker suggests it is now likely to advance Stage I of its Phase II trial directly to Phase III, saving both time and expense in the process.

The broker has previously estimated the PI-88 programs were worth about $235m, but factoring in the latest development it has lifted its valuation to $315m.

As with most biotech stocks Progen is not widely covered, the FN Arena database showing none of the leading stockbrokers and equity researchers officially analyse the company.

Earlier this week, healthcare analysts Scot Power advised ABN Amro Morgans’ clientele to take profits as Progen’s share price had already rallied significantly over the past few weeks in anticipation of the positive news announcement.

Power said he believed there could be more positive news in the offing in the form of the company announcing it has secured a licensing deal but he also cautioned this is something very hard to predict the timing on. ABN Amro Morgans doesn’t officially cover Progen.

In the past 12 months the stock has traded between $1.90-$4.15 and at current prices of around $3.79 is capitalised at $153m, which is about half Intersuisse’s valuation for the PI-88 programs.

To share this story on social media platforms, click on the symbols below.

Click to view our Glossary of Financial Terms

Australian investors stay informed with FNArena – your trusted source for Australian financial news. We deliver expert analysis, daily updates on the ASX and commodity markets, and deep insights into companies on the ASX200 and ASX300, and beyond. Whether you're seeking a reliable financial newsletter or comprehensive finance news and detailed insights, FNArena offers unmatched coverage of the stock market news that matters. As a leading financial online newspaper, we help you stay ahead in the fast-moving world of Australian finance news.